Investing.com - Neurocrine (NASDAQ: NBIX) reported first quarter EPS of $-0.51, $1.14 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $410M versus the consensus estimate of $410.82M.
Guidance
Neurocrine sees FY 2023 revenue of $1.67B-$1.77B versus the analyst consensus of $1.81B.
Neurocrine's stock price closed at $103.45. It is down -5.98% in the last 3 months and up 17.02% in the last 12 months.
Neurocrine saw 0 positive EPS revisions and 11 negative EPS revisions in the last 90 days. See Neurocrine's stock price’s past reactions to earnings here.
According to InvestingPro, Neurocrine's Financial Health score is "great performance".
Check out Neurocrine's recent earnings performance, and Neurocrine's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar